U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. FDA Organization
  4. Center for Drug Evaluation and Research | CDER
  5. Office of Infectious Diseases (OID)
  1. Center for Drug Evaluation and Research | CDER

Office of Infectious Diseases (OID)


The Office of New Drugs is undergoing a reorganization. This site will be updated in the near future. Please check back often. For more information, please visit: Reorganization of the Office of New Drugs with Corresponding Changes to the Office of Translational Sciences and the Office of Pharmaceutical Quality. Until this page is updated, please contact druginfo@fda.hhs.gov or newdrugstransitionteam@fda.hhs.gov for updates and additional information.

Mission

The Office of Infectious Diseases (OID) consists of three review divisions: The Division of Anti-Infectives (DAI), the Division of Antivirals (DAV), and the Division of Pharm/Tox for Infectious Diseases (DPT-ID). The Immediate office oversees the development, review, and regulation of applications as well as issues related to toxicology for drug and biologic products reviewed in these divisions.

Immediate Office

Director: John Farley, M.D., MPH
Deputy Director: TBD
Associate Director for Research: Thushi Amini, Ph.D.
Associate Director for Regulatory Science: Sunita Shukla, Ph.D., M.P.H.

Division of Anti-Infective (DAI)

Director: Sumathi Nambiar, M.D., M.P.H.
Deputy Director: Dmitri Iarikov, M.D., Ph.D.
Regulatory Operations Chief Project Managers: Maureen Dillon-Parker and Carmen DeBellas

Division of Antiviral (DAV)

Director: Debra Birnkrant, M.D.
Deputy Director: Jeffery Murray, M.D., M.P.H
Regulatory Operations Chief Project Manager: Karen Winestock

Division of Transplant and Ophthalmology Products (DTOP)

The Division of Ophthalmology will be part of the Office of Specialty Medicine beginning in mid-Jan 2020.  For more information, please visit: Reorganization of the Office of New Drugs with Corresponding Changes to the Office of Translational Sciences and the Office of Pharmaceutical Quality.

Director: Ozlem Belen, M.D (Acting)
Deputy Director: Wiley Chambers, M.D.

OID Research Activities

Overview of research needs, requests for information (RFIs), public workshops/meetings, opportunities for collaboration, externally awarded research studies, and other important research.

OID Regulatory Science Activities

Contact Us

Mailing Address:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Infectious Diseases
10903 New Hampshire Avenue
Silver Spring, MD 20993
Phone: (301) 796-1300
Fax: (301) 796-9887

Resources For You